Developing a new way to deliver anti-thrombotic agents safely to prevent blood clots.
BC-mediated delivery of thromboprophylaxis
This study is looking at new ways to safely deliver blood-thinning medications to people who are at risk of blood clots and bleeding, especially after surgery, by targeting the treatment directly to where it's needed in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10887615 on NIH RePORTER |
What this research studies
This research focuses on creating innovative drug delivery systems that can safely administer anti-thrombotic agents to patients at risk of both blood clots and bleeding, particularly after surgery. The approach involves targeting red blood cells to optimize the delivery of these agents directly to the sites where they are needed while preventing them from affecting other areas that could lead to complications. The research will utilize advanced models, including humanized systems and transgenic mice, to evaluate the effectiveness and safety of these delivery methods. By understanding how these agents interact with blood cells, the research aims to improve patient outcomes in managing thrombosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing surgery who are at high risk for developing blood clots and experiencing bleeding complications.
Not a fit: Patients who do not have a risk of thrombosis or bleeding, or those not undergoing surgical procedures, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients at risk of thrombosis and bleeding.
How similar studies have performed: Other research has shown promise in using targeted drug delivery systems for anti-thrombotic agents, indicating potential success for this novel approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Muzykantov, Vladimir R — University of Pennsylvania
- Study coordinator: Muzykantov, Vladimir R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.